GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

New Journey Health Technology Group Co 002219.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

1.92

-0.52%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About New Journey Health Technology Group Co

Its shares trade on Shenzhen under the ticker 002219.SZ. It has been listed since 6 March 2008. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.05bn and net income of CN¥30.9m. At that date it held total assets of CN¥6.65bn and shareholders' equity of CN¥1.95bn.

New Journey Health Technology Group Co., Ltd. engages in the manufacturing, sale, research and development of traditional Chinese medicines. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2008-03-06. The firm is mainly engaged in two businesses. The medical service business mainly provides medical services in general hospitals and specialized hospitals. The pharmaceutical manufacturing business is mainly engaged in the research and development, production and sales of pharmaceuticals. The firm mainly conducts its businesses in the domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Providers & Services
Listed since
6 Mar 2008
Employees
7,824
Website
njhtg.com ↗

Leadership

Pay as last reported

  • Mr. Yanglin LinChairman of the Board, since 2021CN¥36,800
  • Ms. Yanling ZhangVice Chairman of the Board, since 2023
  • Mr. Jun LiuChief Financial OfficerCN¥715,700
  • Ms. Lihua SongSenior Vice President, Director, since 2018CN¥1.0m
  • Mr. Chen NieVice PresidentCN¥400,000
  • Mr. Dian ZhuVice President
  • Mr. Hengye GuanDirectorCN¥10,400
  • Mr. Minggui XuDirectorCN¥10,400
  • Ms. Ping XueDirector
  • Ms. Ziqing ZhouDirectorCN¥10,400
  • Ms. Yiting ChiIndependent Director
  • Mr. Chenguang DuIndependent DirectorCN¥20,800

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Chengdu headquarters supports local market dominance in Sichuan province.
  • 7,824 employees ensure robust R&D and production capabilities.
  • Two core businesses cover medical services and pharmaceutical manufacturing.

Weaknesses

  • Reliance on domestic market limits international expansion opportunities.
  • IPO date 6 March 2008 indicates long-standing market presence.
  • Traditional Chinese medicine focus may face regulatory challenges.

Opportunities

  • Growing domestic health care demand in China supports market expansion.
  • Sichuan province's healthcare infrastructure development offers growth.
  • R&D investments in pharmaceuticals can lead to new product launches.

Threats

  • Regulatory changes in traditional Chinese medicine sector pose risks.
  • Competition from domestic pharmaceutical companies intensifies.
  • Economic downturns could reduce healthcare spending in China.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.